Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H15F6N5O.H3O4P |
Molecular Weight | 505.3088 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC3=C(F)C=C(F)C(F)=C3
InChI
InChIKey=IQFYVLUXQXSJJN-SBSPUUFOSA-N
InChI=1S/C16H15F6N5O.H3O4P/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H3,1,2,3,4)/t9-;/m1./s1
Molecular Formula | H3O4P |
Molecular Weight | 97.9952 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H15F6N5O |
Molecular Weight | 407.3136 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity towards other DDP enzymes (DPP- 8 and DPP-9). It has been approved for the treatment of type 2 diabetes in the USA and Europe and is registered by the name Januvia (Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In healthy volunteers and in patients with type 2 diabetes of different ethnic background, the tolerability of different doses given once or twice daily is good. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. Sitagliptin is an incretin enhancer and the first marketed medication belonging to the gliptin class. In fact, no published literature exists regarding incidence or severity of hypoglycemia when sitagliptin is used off-label in combined with insulin therapy. However, is recommended to use methods to avoid hypoglycemia when using this off-label combination. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17352677
Curator's Comment: # Merck in 1999
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17580730 |
18.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | JANUVIA Approved UseJANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1) Important Limitations of Use: •JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. (1.2) •JANUVIA has not been studied in patients with a history of pancreatitis. (1.2, 5.1) 1.1 Monotherapy and Combination Therapy JANUVIA® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [See Clinical Studies (14). Launch Date2006 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
950 nM |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.52 μM × h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Highest studied dose |
unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Vomiting... |
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: |
healthy, 18-45 years n = 77 Health Status: healthy Age Group: 18-45 years Sex: M+F Population Size: 77 Sources: |
|
1700 mg single, oral Overdose Dose: 1700 mg Route: oral Route: single Dose: 1700 mg Sources: |
unknown, 86 years |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 12.5% | 200 mg single, oral Highest studied dose |
unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15, 30 |
no [IC50 >100 uM] | no (co-administration study) Comment: results indicated that sitagliptin was not a time-dependent inhibitor of CYP3A4; sitagliptin did not meaningfully alter the pharmacokinetics of simvastatin. Page: 15, 30 |
||
Page: 6.0 |
no | |||
Page: 15.0 |
no | |||
Page: 6.0 |
no | |||
Page: 9.0 |
no | |||
Page: 15.0 |
no | no (co-administration study) Comment: sitagliptin had no inhibitory effect on the P-gp mediated transport of digoxin, verapmil, ritonavir, adn vinblastine Page: 15.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
inconclusive | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 4, 42 |
yes | |||
Page: 4, 42 |
yes | |||
Page: 4, 15 |
yes | |||
Page: 4, 15 |
yes | yes (co-administration study) Comment: cyclosporin A significantly inhibited P-gp transport of sitagliptin Page: 4, 15 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 22, 23 |
PubMed
Title | Date | PubMed |
---|---|---|
Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. | 2006 |
|
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. | 2006 Aug |
|
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | 2006 Dec |
|
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | 2006 Jun |
|
Therapies for the treatment of type 2 diabetes mellitus based on incretin action. | 2006 Jun |
|
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. | 2006 Mar |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | 2006 Nov |
|
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. | 2006 Nov |
|
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. | 2006 Oct |
|
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. | 2006 Sep |
|
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. | 2007 |
|
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2007 |
|
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. | 2007 Apr |
|
beta-cell failure in diabetes and preservation by clinical treatment. | 2007 Apr |
|
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. | 2007 Apr |
|
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. | 2007 Apr |
|
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2]. | 2007 Aug |
|
Incretins: a new treatment option for type 2 diabetes? | 2007 Feb |
|
Sitagliptin. | 2007 Feb |
|
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. | 2007 Feb |
|
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | 2007 Jan |
|
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2007 Jan 1 |
|
Management of comorbid diabetes and cancer. | 2007 Jul |
|
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. | 2007 Jul 11 |
|
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). | 2007 Jun 15 |
|
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. | 2007 May |
|
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. | 2007 Sep |
Sample Use Guides
100 mg once daily. It can be taken with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23849976
Curator's Comment: Sitagliptin therapy enhances circulating angiogenic cell numbers, angiogenesis and blood flow in the critical limb ischemia area.
Adipose tissue from adult-male Fischer 344 rats were cultured in endothelial progenitor cell culture medium for 14 d with (25 μmol/L) or without sitagliptin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:56:43 GMT 2023
by
admin
on
Fri Dec 15 15:56:43 GMT 2023
|
Record UNII |
494P4635I6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID10215789
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
PRIMARY | |||
|
m9960
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
PRIMARY | |||
|
654671-78-0
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
PRIMARY | |||
|
494P4635I6
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
PRIMARY | |||
|
6451150
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
PRIMARY | |||
|
1269630-53-6
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
100000089174
Created by
admin on Fri Dec 15 15:56:43 GMT 2023 , Edited by admin on Fri Dec 15 15:56:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|